title: Comparison of guideline-based control definitions and associations with outcomes in severe or difficult-to-treat asthma.
abstract: BACKGROUND
  The National Asthma Education and Prevention Program put forth guidance on how to measure asthma control. This guidance is flexible regarding how the impairment component of control is assessed.
  
  
  OBJECTIVE
  To evaluate and compare 3 different National Asthma Education and Prevention Program-informed definitions of asthma control and to explore the strength of association between levels of asthma control and future control, asthma-related costs, and health-related quality-of-life utilities.
  
  
  METHODS
  We used descriptive statistics, the weighted K statistic, and regression methods to compare 3 definitions in a large registry cohort and to explore associations with clinical and health economic outcomes.
  
  
  RESULTS
  We followed up 3,061 patients (> or = 12 years old) in a representative sample of severe or difficult-to-treat asthma. At baseline, 9.1%, 17.1%, or 33.5% of patients were considered well controlled depending on the definition. Lung function was not a component of the definition where 33.5% of patients were well controlled. Weighted K statistics comparing the baseline control definitions ranged from 0.36 to 0.67. The adjusted R2 statistic from the models predicting the future odds of being well controlled, mean asthma-related costs, and mean utilities did not yield consistent results for ranking the definitions of control.
  
  
  CONCLUSIONS
  Although all 3 control definitions were correlated with future control and health economic outcomes, there were striking differences in the descriptive results across the definitions, including the proportion of patients in each category of control. Differences among definitions of asthma control may lead to divergent research conclusions or treatment practices. We do not advocate for one particular definition, but we call for standardization of control definitions for specific uses.
authors.affiliation: Pharmaceutical Outcomes Research and Policy Program, University of Washington, Seattle, Washington 98195, USA. campbelj@u.washington.edu
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Campbell
authors.forename: David K
authors.initials: DK
authors.lastname: Blough
authors.forename: Sean D
authors.initials: SD
authors.lastname: Sullivan
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000191:economics / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis* / Q000191:economics / Q000628:therapy*; D015331:Cohort Studies; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012189:Retrospective Studies; D013147:Spirometry / Q000379:methods; D011795:Surveys and Questionnaires
chemical_list: D018927:Anti-Asthmatic Agents